Barcelona, Spain / Cambridge, MA – April 2026 – Nostrum Biodiscovery, a technology developer with proprietary computational platforms and AI tools for drug discovery, today announced the appointment of Ahmad Reza Saadat as Head of Business Development, United States, based at the company’s office at the Cambridge Innovation Center (CIC) in Kendall Square, Cambridge, MA.
Ahmad brings over 26 years of life sciences industry experience spanning drug discovery, corporate strategy, licensing and partnering, M&A, and commercialization. His career includes senior roles at Vertex Pharmaceuticals, Sarepta Therapeutics, Momenta Pharmaceuticals, Epizyme, and Fosun Pharma, where he led late-stage licensing and M&A transactions and built innovative therapeutics pipelines.
Marie-Eve Beaulieu, General Manager of Nostrum Biodiscovery, commented:
“Ahmad’s appointment is a significant step in our North American growth strategy. We have been growing our collaborations with North American partners, and his extraordinary depth of experience positions us to accelerate that momentum. Our computational platforms and AI tools are generating compelling results for drug discovery programs, and we are eager to bring that capability closer to the pharma and biotech community in the US.”
